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Background: In the 1990s, the Japanese Society of Allergology (JSA) standardized Japanese cedar pollen
allergen vaccines. In the present study, the task force for house dust mite (HDM) allergen standardization
of the Committee for Allergens and Immunotherapy of JSA reports the standardization of HDM allergen
vaccines in Japan.
Methods: In vivo allergenic potency was determined by intradermal testing of 51 Japanese adults with
positive serum speciﬁc IgE to HDM allergens. In vitro total IgE binding potency was analyzed by
competition ELISA using a pooled serum, with sera obtained from 10 allergic patients. The amounts of
HDM group 1 (Der 1) and group 2 major allergens in eight HDM allergen extracts were measured by
sandwich ELISAs. Correlation between the in vitro total IgE binding potency and major allergen levels was
analyzed.
Results: We selected a JSA reference HDM extract and determined its in vivo allergenic potency. The
in vitro total IgE binding potency signiﬁcantly correlated with Der 1 content, group 2 allergen content,
and their combined amount, indicating that measurement of major allergen contents can be used as a
surrogate in vitro assay.
Conclusions: The task force determined the in vivo allergenic potency (100,000 JAU/ml) and Der 1
content (38.5 mg/ml) of the JSA reference HDM extract, selected the measurement of Der 1 content as the
surrogate in vitro assay, and decided that manufacturers can label a HDM allergen extract as having a titer
of 100,000 JAU/ml if it contains 22.2e66.7 mg/ml of Der 1.
Copyright © 2015, Japanese Society of Allergology. Production and hosting by Elsevier B.V. All rights reserved.nese Society of Allergology task force report on standardization of house dust mite allergen vaccines” published in
9-40 (in Japanese).
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T. Takai et al. / Allergology International 64 (2015) 181e186182Introduction external application ofmedicationwithin one day of study initiation,
(2) oral antihistamine, oral a- or b-adrenergic agonists, and topicalAllergen-speciﬁc immunotherapy has been performed in gen-
eral medical practice since it was ﬁrst described by Noon in 1911.1e7
Standardization of allergen vaccines/extracts used for therapy and
diagnosis is necessary because their qualities are variable
depending on production methods and manufactured lots.3e5,8e10
In the United States, allergen standardization is based on intra-
dermal testing of allergic patients and the potencies of lots are
determined by appropriate surrogate in vitro assays, which are
based on inhibition of binding of IgE from pooled allergic sera to
solid phase reference allergen extracts, or measurement of speciﬁc
allergen contents in the allergen vaccines.8 In the European Union,
products are standardized using manufacturers' in-house refer-
ences and labeled in manufacturer-speciﬁc units.9 In Japan, the
Japanese Society of Allergology (JSA) standardized Japanese cedar
pollen (JCP) allergen vaccines.11,12 In vivo allergenic potency of the
JSA reference JCP extract was determined by intradermal testing
and measurement of the content of the major allergen Cry j 1 was
selected as the surrogate in vitro assay.
House dust mites (HDMs) are a major allergen source that pro-
vokes allergic rhinitis, asthma, conjunctivitis, and atopic derma-
titis.13,14 However, standardization of HDM allergen vaccines/extracts
basedon intradermal testing in Japanese subjectswithpositive serum
speciﬁc IgE to HDM allergens has not been performed. This report,
produced by the task force for HDM allergen standardization of the
Committee for Allergens and Immunotherapy of JSA, selected a JSA
reference HDM extract, determined its in vivo allergenic potency in
Japanese allergy units (JAU) by intradermal testingofHDM-sensitized
Japanese adults, and determined a surrogate in vitro assay that is
suitable for HDM allergen standardization in Japan.Methods
HDM allergen extracts
Each HDM extract was prepared as a mixture of equivalent vol-
umes of extracts from two mite species, Dermatophagoides pter-
onyssinus (DP) andDermatophagoides farinae (DF).UnitedStates Food
and Drug Administration (FDA) reference extracts, E11-DP (10,000
AU/ml) and E10-DF (10,000 AU/ml), were acquired from the Labo-
ratory of Immunobiochemistry, Division of Bacterial, Parasitic and
Allergenic Products, Ofﬁce of Vaccines Research and Review, Center
for Biologics Evaluation and Research (CBER), FDA. Commercial ex-
tracts for subcutaneous immunotherapy (DP: lot#B3117094 and DF:
lot#F21G6279, 10,000 AU/ml) were purchased from Hollister-Stier
(Spokane, WA, USA). Five extracts identiﬁed by alphabet letters
(Extracts AeE) were obtained from ALK-Abello AS (Hørsholm,
Denmark) and Stallergenes SA (Antony, France). JSA chose an extract
other than those described above as the JSA reference HDM extract.
Measurement of group 1 allergens and in vitro relative IgE binding
potency testing took place in the laboratories of SagamiharaNational
Hospital (Laboratory 1) and Azabu University (Laboratory 2). Mea-
surement of the combined total content of group 2 allergens was
conducted only in Laboratory 1.HDM-sensitized subjects
Inclusion criteria for the HDM-sensitized subjects enrolled in this
studywere: Japanese adults between the age of 20 and 50 yearswho
werepositive forDPorDF-speciﬁc IgE, showing0.70Ua/ml (class 2)
in ImmunoCAP assay (ThermoFisher Scientiﬁc, Uppsala, Sweden).
Subjectswere excluded from the study if they had (a) skin disease on
the forearm that affects intradermal injection reactions; (b) used (1)corticosteroid or immunosuppressive medicine for external appli-
cation to the injection site within one week of study initiation, (3)
tricyclic antidepressants and phenothiazines with an antihistamine
effect within 2 weeks of study initiation, (4) non-selective b-adren-
ergic blockers within 3 weeks of study initiation, (5) systemic
immunosuppressive drugs within 30 days of study initiation, (6)
speciﬁc antibodies within 90 days of study initiation; or if they were
(c) pregnant or were possibly pregnancy on the study day; were
under (d) HDM-speciﬁc immunotherapy; or had (e) severe bronchial
asthma; (f) anaphylaxis to adrenaline; (g) concomitant systemic
diseases such as cardiac, hepatic, renal, and hematologic disorders or
infection that could affect the study trial; or (h) were judged by the
examiners as being inappropriate for study enrollment.
Intradermal testing and collection of serawere conducted at the
Department of OtorhinolaryngologyeHead and Neck Surgery of
Chiba University Graduate School of Medicine, Department of
Otorhinolaryngology of Nippon Medical School, Graduate School of
Medicine, Department of Respiratory Medicine of Saitama Medical
University, and Department of OtorhinolaryngologyeHead and
Neck Surgery of the University of Yamanashi Interdisciplinary
Graduate School of Medicine and Engineering. The ethical review
committee of each institution approved the protocol of this study.
Written informed consent was obtained from all patients before
study enrollment and anonymity was preserved using documents
and methods approved by the ethical review committees.
Intradermal testing
First, we selected a candidate HDM extract as the JSA reference
HDM extract to be used for intradermal testing. The candidate
extract was diluted using the 0.005% Polysorbate 80-added control
solution for intradermal skin testing, “TORI-I”, which contained
0.9% (w/v) NaCl and 0.5% (w/v) phenol (Torii Pharmaceutical, Tokyo,
Japan). The dilution factors were from 37 to 319 (2187e1.162  109).
Control solution for intradermal skin testing, “TORI-I”, was used as
the negative control.
Intradermal testing was performed according to a previously
described method.11,12 The protocol for intradermal testing was
largely based on the FDA protocol except for criteria for deter-
mining the threshold concentration. Brieﬂy, 20 ml of each diluted
HDMextract was administered intradermally into the forearm from
low to high concentrations using 1-ml tuberculin syringes. Fifteen
minutes after the injection, the diameters of the wheal or erythema
were measured based on Ishizaki's criteria15e17 (i.e. positive reac-
tion is deﬁned as presence of awheal or erythematous skin reaction
with a diameter of more than 9 mm or 20 mm, respectively). The
threshold dilution factor was deﬁned as the maximum dilution
factor of diluted extract that can induce a positive reaction.
With respect to the determination of in vivo allergenic potency,
threshold values of all patients were represented as logarithms that
have 3 as the base of the threshold dilution factors, and then an
average value for them was calculated. Values, which were from 9
to 11, 11 to 13, and 13 to 15, were assigned the in vivo allergenic
potencies of 1000 JAU/ml, 10,000 JAU/ml, and 100,000 JAU/ml,
respectively, based on the plan used in the standardization of JCP
allergen vaccines.11,12 With this method, the same titer could be
assigned to extracts with, at the most, a 32-fold (9-fold) difference
in allergenic potencies.
Measurement of HDM group 1 major allergens
The group 1 allergens, Der p 1 and Der f 1, in the HDM extracts
were measured by a previously described method.18 Brieﬂy,
T. Takai et al. / Allergology International 64 (2015) 181e186 183sandwich ELISAs for Der p 1 or Der f 1 were performed using
murine monoclonal antibodies and 92-Dp or 92-Df extract,18,19
respectively, as the standard antigen for ELISA. Previously, the 92-
Dp and 92-Df extracts were prepared from HDM bodies and the
contents of group 1 and group 2 allergens in 92-Dp and 92-Dfwere
determined.18,19 For validation of the measurement obtained by
this method, group 1 allergen content was also determined using
other ELISA kits purchased from Indoor Biotechnologies (Charlot-
tesville, VA, USA) and Nichinichi Pharmaceutical (Mie, Japan).Measurement of the total amount of HDM group 2 major allergens
The total amount of group 2 allergens (Der 2), Der p 2 and Der f
2, was measured using a previously described method.20,21 Brieﬂy,
a sandwich ELISA for Der 2 was performed using rabbit polyclonal
antibodies and a mixture of 92-Dp and 92-Df extracts18,19 as the
standard antigen for ELISA.Sera for in vitro relative IgE binding potency testing
A total of 20 ml of blood sample was taken from 10 randomly
selected patients out of 19 who had 17.5 Ua/ml (class 4) for DP- or
DF-speciﬁc IgE in the ImmunoCAP assay (ThermoFisher). Blood
samples were centrifuged and sera were separated and stored
at 80 C. A pooled serumwas prepared as a mixture of equivalent
volumes of the 10 sera.In vitro relative IgE binding potency testing
Competition ELISA was used to evaluate the inhibition of
allergen-speciﬁc IgE binding as described previously.22 Brieﬂy, the
plates were coated with the JSA reference HDM extract or another
extract (Extract C). The pooled serum (dilution factor: 50) was
mixed with an equivalent volume of each serially diluted inhibitor
extract (ﬁnal serum dilution factor: 100), and after incubation for
30 min at room temperature, the mixtures were added to the wells
of the plates. The allergen-speciﬁc IgE binding to plate wells were
detected with enzyme-conjugated anti-human IgE and a ﬂuoro-
genic substrate. Relative potencies of extracts were calculated as
ratios of the dilution factors of the extracts that gave half the
maximum (50%) ﬂuorescence relative to that of the JSA reference
HDM extract.Statistical analysis
Pearson correlation coefﬁcients for the association between
major allergen content and in vitro relative IgE binding potency
were calculated after logarithmic transformation. P < 0.05 was
regarded as statistically signiﬁcant.Figure 1. Distribution of the threshold values that induced positive reactions in the
intradermal testing of 51 Japanese adults with positive serum speciﬁc IgE to house dust
mite allergens. Prepared dilution factors of the Japanese Society of Allergology refer-
ence house dust mite extract were from 37 (2187) to 319 (1.162  109). A total of 20 ml of
each diluted extract was administered intradermally into the forearm from low to high
concentrations. The diameters of the wheal or erythematous skin reaction were
measured 15 min after the injection. Threshold value: the exponent of the maximum
dilution factor that can induce a positive reaction in each subject.Results
Selection of a HDM allergen extract as the JSA reference HDM extract
We selected one extract, which can be used for intradermal
testing and would be approved for allergen-speciﬁc immuno-
therapy in Japan, as a candidate for the JSA reference HDM extract.
The candidate extract showed appropriate values in terms of in vivo
allergenic potency and HDM group 1 and 2major allergen contents,
as described below. Accordingly, we selected the candidate extract
as the JSA reference HDM extract.Measurement of in vivo allergenic potency of the JSA reference HDM
extract
Fifty-two adults (24 men and 28 women) were enrolled in this
study. Their mean age (±SD) was 32.9 (±6.5) years. Of the 52 par-
ticipants, 42 (80.7%) were diagnosed with persistent allergic
rhinitis and among them, 5 and 4 also had bronchial asthma and
allergic rhinitis provoked by JCP, respectively. Another 4 partici-
pants had bronchial asthma and 1 had cough variant asthma. One
person was excluded from study analysis because the threshold
concentration in intradermal testing could not be examined. Fig. 1
shows the frequency and distribution of threshold values of intra-
dermal testing of the 51 subjects. The average (±SD) threshold
value was 13.22 (±1.43), which corresponded to 100,000 JAU/ml.Major allergen contents in the JSA reference HDM extract
The concentrations of HDM group 1 and group 2 allergens in
HDM extracts designated as 92-Dp and 92-Df had been already
determined.18,19 The group 1 and group 2 allergen contents in the
JSA reference HDM extract were measured by sandwich ELISAs
using the 92-Dp and/or 92-Df extract as the standard antigen for
ELISA (Table 1). Measurement of the group 1 allergens produced
similar results in the two laboratories. The concentrations of Der p
1, Der f 1, and total concentration of Der p 1 and Der f 1 (Der 1) in
the JSA reference HDM extract were (as the geometric means of the
values obtained in the two laboratories) 25.6, 12.9, and 38.5 mg/ml,
respectively. The total concentration of Der p 2 and Der f 2 (Der 2)
measured in Laboratory 1 was 55.5 mg/ml.Validation of measurement of Der p 1 and Der f 1
Other ELISA systems were used to validate the measurement of
Der p 1 and Der f 1 in this study (Table 2). Similar results were
obtained using two commercially available ELISA kits. Lower values
(approximately 20% less) were obtained with the kit purchased
from Indoor Biotechnologies. The standard used in the kit is
designated as an “universal” allergen standard (UAS), which was
developed in the CREATE project funded through the European
Union.23,24 Regardless of whether the monoclonal antibodies were
in the kit from Indoor Biotechnologies or developed in Laboratory 1,
use of UAS as the standard antigen for ELISA resulted in lower
Table 1
House dust mite major allergen content in the Japanese Society of Allergology
reference house dust mite extract.
Concentration (mg/ml)
Group 1 allergens Group 2 allergens
Institute Der p 1 Der f 1 Der 1 Der 2
Laboratory 1 28.2 14.1 42.3 55.5
Laboratory 2 23.2 11.8 35.0 N.D.
Geometric mean 25.6 12.9 38.5
Der p 1, Der f 1, and Der 2 weremeasured by sandwich ELISA in two institutes. Der 1,
combined total of Der p 1 and Der f 1; Der 2, combined total of Der p 2 and Der f 2;
Laboratory 1, Sagamihara National Hospital; Laboratory 2, Azabu University; N.D.,
not determined.
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the small discrepancy was caused by the difference in the deﬁned
concentrations of Der p 1 and Der f 1 between 92-Dp/92-Df and UAS
and was not due to the detection system, such as speciﬁcity of
monoclonal antibodies. The results indicated that the ELISA system
for Der p 1 and Der f 1 developed in Laboratory 1 was valid.
Major allergen contents in the HDM extracts tested
Major allergen contents in the seven HDM extracts other than
the JSA reference HDM extract were measured (Table 3). Five ex-
tracts were from ALK or Stallergenes (Extract AeE) and two were
from CBER/FDA and Hollister-Stier. Similar results were obtained in
the two laboratories (Tables 3, 4, concentration).
Correlation between the major allergen contents and in vitro
relative IgE binding potencies
Competition ELISA was used to evaluate the inhibition of
allergen-speciﬁc IgE binding to plates coatedwith the JSA reference
HDM extract or Extract C. A pooled serum was prepared as a
mixture of equivalent volumes of sera from 10 of 19 patients who
had 17.5 Ua/ml (class 4) for DP- or DF-speciﬁc IgE in the Immu-
noCAP assay. The in vitro total IgE binding potencies of the HDM
extracts relative to the JSA reference HDM extract were determined
(Tables 3, 4, in vitro relative potency). Similar results were obtained
using JSA reference HDM extract-coated plates and Extract C-
coated plates. Similar results were obtained in the two laboratories.
Correlation between major allergen contents and the relative
IgE binding potency was analyzed. The relative IgE binding potency
correlated well with each of the concentrations of Der 1 (Figs. 2, 3),Table 2
Comparison of house dust mite group 1 allergen contents in the Japanese Society of
Allergology reference house dust mite extract determined by sandwich ELISAs using
different antibodies and standards.
Institute ELISA Concentration (mg/ml)
Antibodiesy Standardz Der p 1 Der f 1 Der 1
Lab1 Lab1 92-Dp/92-Df 28.2 14.1 42.3
Lab1 UAS 22.1 9.69 31.8
Indoor 92-Dp/92-Df 27.4 14.6 42.0
Indoor UAS 22.3 11.7 34.0
Nichinichi Nichinichi 24.3 13.6 37.9
Lab2 Lab1 92-Dp/92-Df 23.2 11.8 35.0
Indoor 92-Dp/92-Df 22.1 14.0 36.1
Der p 1 and Der f 1 were measured by sandwich ELISA in two institutes.
Der 1, combined total of Der p 1 and Der f 1; Lab1, Sagamihara National Hospital;
Lab2, Azabu University; UAS, universal allergen standard; Indoor, Indoor Bio-
technologies; Nichinichi, Nichinichi Pharmaceutical.
y Capture and detection antibodies used in ELISA.
z Standards with deﬁned concentrations used in ELISA.Der 2, and combined total of Der 1 and Der 2 (Der 1þDer 2) (Fig. 2).
Pearson correlation coefﬁcients were greater than 0.9 and were
statistically signiﬁcant.
Discussion
In the 1990s, JSA standardized the JCP allergen vaccines/ex-
tracts.11,12 The JSA standard JCP extract showed an in vivo allergenic
potency of 10,000 JAU/ml. The unit JAU11,12 was determined by
intradermal testing, similar to the bioequivalent allergy unit (BAU)
and the allergy unit (AU) deﬁned by FDA,8,25e27 but criteria for the
reaction threshold are different between JAU and BAU/AU, and the
injection volume is 20 ml for JAU and 50 ml for BAU/AU. JSA selected
measurement of Cry j 1 content as the surrogate in vitro assay for
determining the potencies of other JCP extracts, with the concen-
tration of 12.5 mg/ml of Cry j 1 corresponding to 10,000 JAU/ml. JSA
decided that manufacturers can label JCP extracts as having a titer
of 10,000 JAU/ml if they contain 7.3e21 mg/ml of Cry j 1 i.e., within a
range that is approximately three times the lowest value, the
geometric center of which is 12.5 mg/ml.11,12 In the present study,
the task force selected a JSA reference HDM extract, determined its
in vivo allergic potency in JAU using the same method for JCP
allergen standardization, and analyzed the correlation between the
in vitro total potency determined by IgE binding inhibition ELISA
and the major allergen contents in eight HDM extracts.
Through intradermal testing of 51 Japanese HDM-sensitized
adults, the in vivo allergenic potency of the candidate for the JSA
reference HDM extract was determined as 100,000 JAU/ml. As the
candidate extract showed an appropriate in vivo allergenic potency
(Fig.1) andmajor allergen contents (Table 1), we decided to use it as
the JSA reference HDM extract. Surrogate in vitro assay to deter-
mine the potencies of extracts from different manufacturers and
lots can be based on inhibition of binding of IgE frompooled allergic
sera to a reference allergen extract, or measurement of speciﬁc
allergen contents in the allergen vaccines/extracts. In the United
States, FDA adopted relative IgE binding potency determined by IgE
binding inhibition assay for HDM and mold allergen vaccines;
speciﬁc allergen contents for short ragweed pollen and cat allergen
vaccines (Amb a 1 and Fel d 1, respectively); and enzymatic activity
(hyaluronidase and phospholipases) for Hymenoptera venom
allergen vaccines.8 It has been reported that the major allergen
content correlates with the relative IgE binding potency.28e30
Among more than 20 groups of HDM allergens, group 1 and 2 al-
lergens are considered the major allergens, although some reports
showed that other HDM allergens were also important, albeit less
so than the major allergens.13,14 We judged that measurement of
HDM major allergens is appropriate as a surrogate assay because
the relative IgE binding potency correlated well with each of the
major allergen contents (Figs. 2, 3).
The in vitro measurement of major allergen content has some
advantages as the surrogate assay for allergen standardization i.e., it
can determine absolute and not relative values, and does not need
sera in which differing individual titers are seen. Species-speciﬁc
ELISAs using monoclonal antibodies to measure each HDM group
1 allergen, Der p 1 and Der f 1, with high accuracy are available
commercially (see the Methods section). However, those for each
group 2 allergen, Der p 2 and Der f 2, are not widely available, and
the total contents of Der p 2 and Der f 2 (Der 2) determined by ELISA
using polyclonal antibodies in the present study are approximate
values. Therefore, we selected measurement of the total content of
Der p 1 and Der f 1 (Der 1) as the surrogate in vitro assay. We
determined that the in vivo allergenic potency and Der 1 content of
the JSA reference HDM extract were 100,000 JAU/ml and 38.5 mg/
ml, respectively. Similar to the previous JCP allergen standardiza-
tion,11,12 we decided that manufacturers can label an HDM allergen
Table 3
House dust mite major allergen contents and in vitro total IgE binding potencies of the eight house dust mite extracts determined in Laboratory 1.
Sample Concentration (mg/ml)y In vitro relative potencyz
Der p 1 Der f 1 Der 1 Der 2 Der 1 þ Der 2 JSA coating Extract C coating
JSA 28.2 14.1 42.3 55.5 97.8 1.00 1.00
CBER/FDA 16.7 16.3 33.0 19.6 52.6 0.56 0.51
Hollister-Stier 10.1 2.54 12.6 11.3 23.9 0.35 0.33
Extract A 80.0 54.2 134 254 388 4.89 4.85
Extract B 2.69 0.98 3.67 6.76 10.4 0.14 0.13
Extract C 30.9 52.7 83.6 45.8 129 1.83 2.54
Extract D 3.59 2.50 6.09 2.38 8.47 0.08 0.16
Extract E 2.27 5.45 7.72 3.28 11.0 0.15 0.26
Der 1, combined total of Der p 1 and Der f 1; Der 2, combined total of Der p 2 and Der f 2; JSA, JSA reference house dust mite extract.
y Der p 1, Der f 1, and Der 2 were measured by sandwich ELISA.
z In vitro total IgE binding potency relative to the Japanese Society of Allergology (JSA) reference house dust mite extract was determined on the basis of the results of a
competition ELISA that measures the inhibition of allergen-speciﬁc IgE binding to plates coated with the JSA reference house dust mite extract (JSA coating) or Extract C
(Extract C coating).
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22.2e66.7 mg/ml of Der 1 i.e., within a range that is approximately
three times the lowest value, the geometric center of which is
38.5 mg/ml.
We validated the measurement of Der p 1 and Der f 1 (Table 2).
The amounts of group 1 and group 2 allergens in 92-Dp and 92-Df
extracts were determined previously in Laboratory 118, 19. The
measurement of the concentrations of puriﬁed group 1 and group 2
allergens previously used as the standard antigens for the ELISA
that determine the major allergen contents in 92-Dp and 92-Df
were based on absorbance at 280 nm. UAS is composed of eight
puriﬁed allergens (Der p 1, Der f 1, Der p 2, Fel d 1, Can f 1, Rat n 1,
Mus m 1, and Bla g 2) and the concentrations of the allergens were
determined by amino acid analysis.23,24 The difference in the
original methods for determining the concentrations of the stan-
dard antigens for ELISA might have caused the lower values
(approximately 20% less) obtained by the Indoor Biotechnologies
kit compared with the ELISA developed in Laboratory 1 (Table 2).
In conclusion, the task force (1) selected the JSA reference HDM
extract and determined its in vivo allergenic potency via intrader-
mal testing, (2) showed the correlation between in vitro IgE binding
potency and major allergen contents, and selected measurement of
Der 1 content as the surrogate in vitro assay for determining the
potencies of other HDM extracts by deﬁning 38.5 mg/ml of Der 1 as
100,000 JAU/ml. Furthermore, (3) the task force decided thatTable 4
House dust mite group 1 allergen contents and in vitro total IgE binding potencies of
the eight house dust mite extracts determined in Laboratory 2.
Sample Concentration (mg/ml) In vivo relative potency
Der p 1 Der f 1 Der 1 JSA coatingy Extract C
coatingz
JSA 23.2 11.8 35.0 1.00 1.00
CBER/FDA 17.6 13.2 30.8 0.71 0.75
Hollister-Stier 9.25 1.79 11.0 0.34 0.34
Extract A 80.5 49.5 130 5.75 5.71
Extract B 2.28 0.93 3.21 0.14 0.14
Extract C 38.8 54.2 93.0 1.47 2.11
Extract D 3.40 4.08 7.48 0.11 0.16
Extract E 2.24 6.87 9.11 0.12 0.20
Der 1, combined total of Der p 1 and Der f 1; Der 2, combined total of Der p 2 and Der
f 2; JSA, JSA reference house dust mite extract.
y Der p 1, Der f 1, and Der 2 were measured by sandwich ELISA.
z In vitro total IgE binding potency relative to the Japanese Society of Allergology
(JSA) reference house dust mite extract was determined on the basis of the results of
a competition ELISA that measures the inhibition of allergen-speciﬁc IgE binding to
plates coated with the JSA reference house dust mite extract (JSA coating) or Extract
C (Extract C coating).manufacturers can label a HDM allergen extract as having a titer of
100,000 JAU/ml if it contains 22.2e66.7 mg/ml of Der 1 i.e., within a
range that is approximately three times the lowest value. Der 1
contents can be measured by appropriate methods such as
commercially available sandwich ELISAs (see the Methods section).
JSA is planning to store and distribute the JSA reference HDM
extract. The manufacturers of HDM allergen vaccines would ﬁndFigure 2. Correlation between house dust mite major allergen contents and in vitro
total IgE binding potencies of the eight house dust mite extracts determined in Lab-
oratory 1. The values in Table 3 were used for the analysis. In vitro total IgE binding
potency relative to the Japanese Society of Allergology (JSA) reference house dust mite
extract was determined based on the results of the competition ELISA that measured
the inhibition of allergen-speciﬁc IgE binding to plates coated with the JSA reference
house dust mite extract (A) or Extract C (B). r: Pearson correlation coefﬁcient. *p < 0.01.
Figure 3. Correlation between house dust mite group 1 allergen contents and in vitro
total IgE binding potencies of the eight house dust mite extracts determined in Lab-
oratory 2. The values in Table 4 were used for the analysis. In vitro total allergenic
potency relative to the Japanese Society of Allergology (JSA) reference house dust mite
extract was determined based on the results of the competition ELISA that measured
the inhibition of allergen-speciﬁc IgE binding to plates coated with the JSA reference
house dust mite extract (A) or Extract C (B). r: Pearson correlation coefﬁcient. *p < 0.01.
T. Takai et al. / Allergology International 64 (2015) 181e186186the HDM extract useful as the standard antigen for ELISAs that
measure the amounts of Der p 1 and Der f 1.
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